Review of ranibizumab trials for neovascular age-related macular degeneration

Seminars in Ophthalmology

Volumn 26, Issue 6, 2011, Pages 372-379

  Patel, Ravi D ^a   Momi, Rominder S ^a   Hariprasad, Seenu M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anchor; Catt; Marina; Pier; Pronto; Sailor; Sustain

Indexed keywords

RANIBIZUMAB; SODIUM CHLORIDE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; EYE INFLAMMATION; HUMAN; LENS DISEASE; NEOVASCULAR AGE RELATED MACULA DEGENERATION; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 80455129670     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.570845     Document Type: Review

References (31)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
2. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26.
3. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1.
4. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002;64:162-9.
5. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-93.
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 2006;355:1432-44.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2006;355:1419-31.
8. Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs 2007;67:1199-206.
9. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007 Dec;144(6):850-857.
10. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
11. Sadda SR, Stoller G, Boyer DS, et al Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year ANCHOR study. Retina. 2010;30(9):1390-1399.
12. Kaiser PK, Blodi BA, Shaprio H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;1868-1875.
13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
14. Regillio CD, Brown DM, Abraham P, et al Randomized double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
15. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-324.
16. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
17. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
18. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial [abstract]. Invest Ophthalmol Vis Sci 2008;49:Eabstract 273.
19. Holz FG. SOE: Flexibly dosed ranibizumab in patients with neovascular AMD: Twelvemonth interim results of the SUSTAIN Trial. Abstract PA078 presented at the AAO/SOE Joint Annual Meeting, 8-11 November 2008, Atlanta. http:// www.aao.org/aao/customcf/onlineprogram2008/tnt-getevtlongaao02. cfm?subsystem=
20. Kirchhof B, Kellner U, Holz FG, et al. Visual acuity and central retinal thickness response profiles and treatment patterns in patients with neovascular AMD treated with ranibizumab in the SUSTAIN study. Presented at the 2009 Association for Research in Vision and Ophthalmology Annual Meeting in Fort Lauderdale, Florida; May 3-7, 2009. ARVO Poster Abstract #D1099.
21. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study: Exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macular degeneration. 2008. 8th EURETINA Congress, 22-25 May 2008, Vienna.
22. Simader C, Bolz M, Ritter M, et al. Comparison of treatment effects of ranibizumab on visual acuity, retinal thickness and retinal morphology when administered monthly vs. quarterly with different dosing regimens in the EXCITE trial. Presented at the 2009 Association for Research in Vision and Ophthalmology Annual Meeting in Fort Lauderdale, Florida; May 3-7, 2009. ARVO Poster Abstract #3094.
23. Eldem B. Visual acuity response profiles of patients with choroidal neovascular AMD treated with quarterly dosing of ranibizumab in the EXCITE study. Presented at the Combined meeting of the American Society of Retina Specialists, The Macula Society, and The Retina Society in New York, New York; September 30-October 4, 2009. Retina Congress Abstract.
24. Awh CC. Horizon extension trial of ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): First-year safety and efficacy results [abstract]. Presented at 26th Annual Meeting of the American Society of Retina Specialists; October 11-15, 2008, Maui, HI.
25. Feiner L, Ehrlich J, Ward J, et al. Classification and regression tree analysis to identify predictive factors for visual acuity outcomes in ranibizumab trials. Presented at the 2009 Association for Research in Vision and Ophthalmology Annual Meeting in Fort Lauderdale, Florida; May 3-7, 2009. ARVO Poster #D1091.
26. Antoszyk AN, Tuomi L, Chung CY, Singh A. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): 2-year results. Am J Ophthalmol.
27. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sep;116(9):1731-9.
28. Regillo CD, Francom S, Rubio R. Ranibizumab (LUCENTIS) safety in wet age-related macular degeneration: SAILOR study results. Presented at the 2008 Annual Meeting of the American Academy of Ophthalmology in Atlanta, Georgia; November 8-11, 2008. AAO Poster #PO263.
29. Ferrone PJ. Efficacy of ranibizumab (LUCENTIS) treatment in patients with neovascular age related macular degeneration: Subgroup analysis of SAILOR study cohort 1. Presented at the 26th Annual Meeting of the American Society of Retinal Specialists in Maui, Hawaii; October 11-15, 2008. ASRS Oral presentation.
30. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br J Ophthalmol. 2010 Jan;94(1):2-13.
31. The CATT Research Group, Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2011 Apr 28. [Epub ahead of print]